IL6 and COVID-19: Moreover, it seems that Sitagliptin has proven efficacy against acute respiratory distress syndrome (ARDS), the common causes of COVID-19-related death, because this drug inhibits IL-6, IL-1, and TNF in individuals with lung injury [27].